Laveena Chhatwani, MD
Pulmonary Disease · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
13 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chhatwani’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
13 of 13 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A99306 · Current
Licensed to practise in California · since 2007 · expires 2028-08-31 · University of Bombay, Topiwala National Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$62,128
Medicare paid this office $62,128 for 112 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 60 | $34,491 | $104 |
| Critical care, first 30-74 minutes | 16 | $12,704 | $181 |
| Long return visit (40+ min) | 54 | $9,092 | $126 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 12 | $1,688 | $94 |
| Hospital discharge day management, more than 30 minutes | 14 | $1,564 | $104 |
Who their Medicare patients are
112 Original Medicare patients in 2024. Average age 63 · Under 65 38% · Women 38% · Also on Medicaid 44% · Health risk score 4.82. Sicker patients than 9 in 10 peers; the typical pulmonary disease clinician is at 2.13.
Conditions among them: High blood pressure 75% · Chronic kidney disease 75% · Diabetes 71% · COPD 56% · Atrial fibrillation 54% · Heart failure 51% · Coronary heart disease 47% · Depression 34% · Dementia 14% · Cancer 11% · Stroke 11%.
The office billed $324,806, Medicare allowed $79,529 and paid $62,128; for 532 services of 13 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 112 | 532 | 63 | 4.82 | $324,806 | $62,128 |
| 2023 | 144 | 1,133 | 63 | 3.73 | $705,003 | $138,439 |
| 2022 | 134 | 1,068 | 61 | 3.77 | $650,841 | $122,108 |
| 2021 | 130 | 690 | 60 | 3.99 | $430,050 | $83,491 |
| 2020 | 146 | 490 | 61 | 3.62 | $200,574 | $38,920 |
| 2019 | 210 | 1,327 | 61 | 3.67 | $369,813 | $91,069 |
| 2018 | 190 | 878 | 59 | 3.69 | $315,133 | $67,957 |
| 2017 | 173 | 944 | 60 | 3.61 | $511,285 | $97,067 |
| 2016 | 126 | 561 | 60 | 3.66 | $247,364 | $58,091 |
| 2015 | 97 | 263 | 58 | 3.80 | $94,630 | $23,980 |
| 2014 | 126 | 544 | 62 | 3.71 | $122,135 | $36,818 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 73 | $72,386 | $109 |
| Critical care, first 30-74 minutes | 20 | $27,506 | $192 |
| Long return visit (40+ min) | 87 | $16,323 | $134 |
| Hospital discharge day management, more than 30 minutes | 33 | $4,391 | $107 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 16 | $2,978 | $85 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,470 | $145 |
2022: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 63 | $57,439 | $94 |
| Critical care, first 30-74 minutes | 22 | $29,092 | $195 |
| Long return visit (40+ min) | 89 | $18,942 | $127 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 19 | $3,424 | $180 |
| Hospital discharge day management, more than 30 minutes | 21 | $2,442 | $98 |
2021: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 45 | $29,566 | $94 |
| Long return visit (40+ min) | 91 | $23,003 | $129 |
| Critical care, first 30-74 minutes | 14 | $19,629 | $196 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 20 | $4,989 | $185 |
| Hospital discharge day management, more than 30 minutes | 18 | $2,104 | $100 |
2020: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 33 | $17,643 | $94 |
| Long return visit (40+ min) | 53 | $6,579 | $103 |
| Hospital discharge day management, more than 30 minutes | 15 | $1,693 | $100 |
| Long return visit (40+ min) | 11 | $997 | $83 |
| Test to measure expiratory airflow and volume | 89 | $737 | $6 |
| Test to examine how well the lungs exchange gases | 11 | $66 | $6 |
2019: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 60 | $45,467 | $94 |
| Long return visit (40+ min) | 118 | $18,594 | $99 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 32 | $7,470 | $182 |
| Hospital discharge day management, more than 30 minutes | 28 | $3,471 | $99 |
| Test to measure expiratory airflow and volume | 151 | $3,352 | $8 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 14 | $3,076 | $123 |
| Test to examine how well the lungs exchange gases | 29 | $356 | $8 |
2018: 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 47 | $23,499 | $94 |
| Long return visit (40+ min) | 130 | $20,133 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 27 | $6,549 | $182 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 29 | $3,617 | $93 |
| Hospital discharge day management, more than 30 minutes | 18 | $2,173 | $99 |
| Test to measure expiratory airflow and volume | 90 | $1,435 | $8 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 21 | $232 | $11 |
| Test to examine how well the lungs exchange gases | 23 | $197 | $8 |
2017: 9 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 57 | $34,214 | $93 |
| Critical care, first 30-74 minutes | 14 | $19,234 | $196 |
| Long return visit (40+ min) | 114 | $19,095 | $95 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 26 | $6,345 | $181 |
| Hospital discharge day management, more than 30 minutes | 32 | $4,517 | $98 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 30 | $4,503 | $96 |
| New patient visit (60+ min) | 11 | $1,654 | $150 |
| Test to measure expiratory airflow and volume | 36 | $304 | $7 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 22 | $284 | $11 |
2016: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 39 | $22,685 | $93 |
| Long return visit (40+ min) | 96 | $17,644 | $99 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $3,605 | $180 |
| Hospital discharge day management, more than 30 minutes | 18 | $2,139 | $97 |
| New patient visit (60+ min) | 11 | $1,647 | $150 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 12 | $1,617 | $108 |
2015: 2 services
| Long return visit (40+ min) | 72 | $9,363 | $87 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $8,933 | $92 |
2014: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 34 | $13,640 | $74 |
| Long return visit (40+ min) | 61 | $8,328 | $82 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 45 | $7,265 | $53 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 18 | $1,890 | $99 |
| Return visit (30+ min) | 16 | $1,081 | $54 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 12 | $1,004 | $77 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 12 | $643 | $29 |
Medicaid work
$4,226 in 2024
Medicaid paid $4,226 for 149 billed services this clinician did in 2024, up to 15 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 149 | $4,226 |
| 2024 | 149 | 1 | 15 | $4,226 |
| 2023 | 514 | 2 | 31 | $20,722 |
| 2022 | 200 | 2 | 19 | $7,950 |
| 2021 | 240 | 2 | 22 | $11,749 |
| 2020 | 62 | 2 | 26 | $580 |
| 2019 | 121 | 1 | 25 | $740 |
| 2018 | 78 | 2 | 23 | $4,608 |
See the largest Medicaid services in earlier years
2023
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 424 | $15,727 |
| Long return visit (40+ min) | 90 | $4,995 |
2022
| Long return visit (40+ min) | 70 | $4,051 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 130 | $3,899 |
2021
| Long return visit (40+ min) | 126 | $7,115 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 114 | $4,633 |
2020
| Long return visit (40+ min) | 14 | $296 |
| Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation | 48 | $284 |
2019
| Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation | 121 | $740 |
2018
| Long return visit (40+ min) | 56 | $4,413 |
| Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation | 22 | $195 |
Drugs they prescribed that Part D paid
$540,318
Pharmacies billed $540,318 in 2024. Most of that is one immune-globulin drugs at about $29,000 a fill for a small number of people.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,032) in 2024. At or below the middle of the specialty; the typical pulmonary disease clinician is at 0%.
968 generic and fewer than 11 brand-name prescriptions · $540,318 in drug cost · 159 antibiotic prescriptions to 36 people · 13 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Panzyga | Immune globulin | 12 | $344,904 | $28,742 |
| Creon | None | 16 | $67,004 | $4,188 |
| Posaconazole | None | 45 | $56,732 | $1,261 |
| Ambisome | None | 12 | $13,985 | $1,165 |
| Everolimus | None | 15 | $9,437 | $629 |
See all 31 drugs
| Panzyga | Immune globulin | 12 | $344,904 | $28,742 |
| Creon | None | 16 | $67,004 | $4,188 |
| Posaconazole | None | 45 | $56,732 | $1,261 |
| Ambisome | None | 12 | $13,985 | $1,165 |
| Everolimus | None | 15 | $9,437 | $629 |
| Valganciclovir | None | 30 | $5,275 | $176 |
| Mycophenolate Mofetil | None | 22 | $4,612 | $210 |
| Atovaquone | None | 14 | $4,004 | $286 |
| Tacrolimus | None | 64 | $3,395 | $53 |
| Itraconazole | None | 34 | $3,336 | $98 |
| Sps | None | 12 | $1,772 | $148 |
| Pantoprazole | None | 137 | $1,001 | $7 |
| Sodium Polystyrene Sulfonate | None | 13 | $829 | $64 |
| Clotrimazole | None | 21 | $776 | $37 |
| Sulfamethoxazole-Trimethoprim | None | 86 | $381 | $4 |
| Acyclovir | None | 37 | $344 | $9 |
| Prednisone | None | 58 | $294 | $5 |
| Rosuvastatin | None | 19 | $203 | $11 |
| Azithromycin | None | 43 | $183 | $4 |
| Potassium Chloride | None | 17 | $151 | $9 |
| Sertraline | None | 12 | $100 | $8 |
| Pravastatin | None | 21 | $93 | $4 |
| Glipizide | None | 25 | $90 | $4 |
| Warfarin | None | 15 | $83 | $6 |
| Fluticasone Propionate | None | 13 | $69 | $5 |
| Levothyroxine | None | 12 | $66 | $6 |
| Tamsulosin | None | 14 | $41 | $3 |
| Metoprolol | None | 17 | $38 | $2 |
| Quetiapine | None | 13 | $33 | $3 |
| Amoxicillin | None | 20 | $30 | $1 |
| Amlodipine Besylate | None | 17 | $11 | $1 |
Year by year
| 2024 | 1,032 | 115 | 0% (0) | None | $540,318 |
| 2023 | 964 | 112 | 0% (0) | 8% | $439,894 |
| 2022 | 900 | 112 | 0% (0) | 7% | $248,211 |
| 2021 | 859 | 106 | 0% (0) | 8% | $162,731 |
| 2020 | 1,174 | 104 | 0% (0) | None | $263,015 |
| 2019 | 2,008 | 147 | None | 13% | $866,656 |
| 2018 | 779 | 106 | 0% (0) | None | $309,022 |
| 2017 | 334 | 45 | None | None | $124,853 |
| 2016 | 139 | 38 | 0% (0) | None | $69,216 |
| 2015 | 179 | 34 | None | 12% | $18,588 |
| 2014 | 145 | 36 | None | 22% | $38,786 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 25 drugs
| Posaconazole | 57 | $170,901 | $2,998 |
| Atovaquone | 32 | $20,902 | $653 |
| Itraconazole | 40 | $18,853 | $471 |
| Ambisome | 13 | $16,674 | $1,283 |
| Valganciclovir | 47 | $12,770 | $272 |
| Combivent Respimat | 12 | $9,052 | $754 |
| Advair Diskus | 15 | $6,492 | $433 |
| Tacrolimus | 20 | $2,782 | $139 |
| Clotrimazole | 25 | $2,462 | $98 |
| Enoxaparin | 12 | $1,696 | $141 |
| Pantoprazole | 106 | $1,474 | $14 |
| Acyclovir | 51 | $1,040 | $20 |
| Sulfamethoxazole-Trimethoprim | 102 | $657 | $6 |
| Azithromycin | 44 | $475 | $11 |
| Gabapentin | 12 | $357 | $30 |
| Potassium Chloride | 17 | $342 | $20 |
| Rosuvastatin | 32 | $303 | $9 |
| Prednisone | 30 | $278 | $9 |
| Pravastatin | 24 | $213 | $9 |
| Fluticasone Propionate | 20 | $155 | $8 |
| Amlodipine Besylate | 14 | $150 | $11 |
| Glipizide | 24 | $94 | $4 |
| Metoprolol | 27 | $93 | $3 |
| Sertraline | 11 | $92 | $8 |
| Metoprolol | 14 | $66 | $5 |
2022: 24 drugs
| Posaconazole | 23 | $69,311 | $3,014 |
| Atovaquone | 19 | $26,163 | $1,377 |
| Itraconazole | 35 | $23,816 | $680 |
| Combivent Respimat | 19 | $8,879 | $467 |
| Symbicort | 14 | $6,141 | $439 |
| Valganciclovir | 33 | $3,369 | $102 |
| Tacrolimus | 22 | $2,748 | $125 |
| Acyclovir | 62 | $1,180 | $19 |
| Rosuvastatin | 41 | $982 | $24 |
| Clotrimazole | 16 | $972 | $61 |
| Pantoprazole | 69 | $766 | $11 |
| Sulfamethoxazole-Trimethoprim | 98 | $763 | $8 |
| Prednisone | 39 | $456 | $12 |
| Mycophenolate Mofetil | 13 | $419 | $32 |
| Fluticasone Propionate | 23 | $259 | $11 |
| Alendronate | 20 | $221 | $11 |
| Warfarin | 17 | $194 | $11 |
| Metoprolol | 37 | $185 | $5 |
| Amlodipine Besylate | 20 | $153 | $8 |
| Atorvastatin | 29 | $145 | $5 |
| Furosemide | 22 | $145 | $7 |
| Sertraline | 16 | $132 | $8 |
| Tamsulosin | 20 | $122 | $6 |
| Metoprolol | 12 | $43 | $4 |
2021: 22 drugs
| Posaconazole | 17 | $44,047 | $2,591 |
| Itraconazole | 20 | $14,236 | $712 |
| Valganciclovir | 23 | $5,418 | $236 |
| Tacrolimus | 33 | $3,243 | $98 |
| Clotrimazole | 25 | $2,100 | $84 |
| Acyclovir | 94 | $1,274 | $14 |
| Sodium Polystyrene Sulfonate | 17 | $1,199 | $71 |
| Mycophenolate Mofetil | 22 | $1,043 | $47 |
| Nystatin | 17 | $960 | $56 |
| Pantoprazole | 58 | $922 | $16 |
| Rosuvastatin | 26 | $807 | $31 |
| Sulfamethoxazole-Trimethoprim | 83 | $670 | $8 |
| Prednisone | 59 | $543 | $9 |
| Azithromycin | 17 | $383 | $23 |
| Diltiazem 24hr Er | 13 | $348 | $27 |
| Pravastatin | 21 | $248 | $12 |
| Amlodipine Besylate | 35 | $221 | $6 |
| Warfarin | 16 | $172 | $11 |
| Metoprolol | 29 | $140 | $5 |
| Furosemide | 21 | $106 | $5 |
| Alendronate | 14 | $78 | $6 |
| Metoprolol | 12 | $69 | $6 |
2020: 22 drugs
| Posaconazole | 25 | $143,666 | $5,747 |
| Valganciclovir | 64 | $20,377 | $318 |
| Itraconazole | 48 | $12,278 | $256 |
| Tacrolimus | 52 | $9,249 | $178 |
| Clotrimazole | 63 | $6,704 | $106 |
| Mycophenolate Mofetil | 40 | $3,897 | $97 |
| Acyclovir | 96 | $1,035 | $11 |
| Pantoprazole | 78 | $994 | $13 |
| Prednisone | 102 | $821 | $8 |
| Sulfamethoxazole-Trimethoprim | 132 | $585 | $4 |
| Diltiazem 24hr Er | 16 | $454 | $28 |
| Pravastatin | 45 | $355 | $8 |
| Rosuvastatin | 25 | $315 | $13 |
| Metoprolol | 64 | $301 | $5 |
| Azithromycin | 25 | $280 | $11 |
| Metoprolol | 16 | $247 | $15 |
| Calcitriol | 13 | $173 | $13 |
| Atorvastatin | 29 | $133 | $5 |
| Potassium Chloride | 11 | $127 | $12 |
| Alendronate | 27 | $118 | $4 |
| Famotidine | 16 | $47 | $3 |
| Amlodipine Besylate | 11 | $26 | $2 |
2019: 42 drugs
| Noxafil | 45 | $280,307 | $6,229 |
| Zenpep | 12 | $114,583 | $9,549 |
| Posaconazole | 17 | $85,293 | $5,017 |
| Cresemba | 19 | $69,275 | $3,646 |
| Valganciclovir | 108 | $60,035 | $556 |
| Itraconazole | 60 | $29,412 | $490 |
| Atovaquone | 15 | $20,532 | $1,369 |
| Cefoxitin | 52 | $19,510 | $375 |
| Sporanox | 13 | $18,381 | $1,414 |
| Advair Diskus | 23 | $11,357 | $494 |
| Zortress | 14 | $10,516 | $751 |
| Clotrimazole | 117 | $8,971 | $77 |
| Amitiza | 18 | $8,769 | $487 |
| Tacrolimus | 96 | $7,011 | $73 |
| Mycophenolate Mofetil | 48 | $3,810 | $79 |
| Sodium Polystyrene Sulfonate | 18 | $1,969 | $109 |
| Pantoprazole | 151 | $1,804 | $12 |
| Azithromycin | 66 | $1,023 | $15 |
| Sulfamethoxazole-Trimethoprim | 165 | $971 | $6 |
| Pravastatin | 74 | $937 | $13 |
| Acyclovir | 100 | $888 | $9 |
| Prednisone | 123 | $798 | $6 |
| Potassium Chloride | 12 | $658 | $55 |
| Ultra-Fine Short Pen Needle | 12 | $547 | $46 |
| Nystatin | 12 | $475 | $40 |
| Alendronate | 71 | $401 | $6 |
| Diltiazem 24hr Er | 12 | $377 | $31 |
| Bupropion Xl | 13 | $361 | $28 |
| Gabapentin | 17 | $357 | $21 |
| Famotidine | 25 | $324 | $13 |
| Rosuvastatin | 11 | $279 | $25 |
| Omeprazole | 20 | $249 | $12 |
| Metoprolol | 53 | $242 | $5 |
| Metoclopramide | 15 | $213 | $14 |
| Fluticasone Propionate | 21 | $187 | $9 |
| Montelukast | 16 | $169 | $11 |
| Furosemide | 20 | $139 | $7 |
| Ranitidine | 12 | $107 | $9 |
| Amlodipine Besylate | 16 | $101 | $6 |
| Glipizide Er | 12 | $101 | $8 |
| Amoxicillin | 22 | $85 | $4 |
| Atorvastatin | 12 | $69 | $6 |
2018: 21 drugs
| Noxafil | 16 | $87,474 | $5,467 |
| Advair Diskus | 51 | $31,500 | $618 |
| Valganciclovir | 19 | $14,784 | $778 |
| Atovaquone | 12 | $13,027 | $1,086 |
| Mycophenolate Mofetil | 33 | $4,504 | $136 |
| Ampicillin-Sulbactam | 19 | $2,305 | $121 |
| Tacrolimus | 30 | $2,275 | $76 |
| Ventolin Hfa | 11 | $1,676 | $152 |
| Clotrimazole | 39 | $1,634 | $42 |
| Azithromycin | 52 | $1,111 | $21 |
| Pantoprazole | 33 | $468 | $14 |
| Prednisone | 61 | $396 | $6 |
| Levofloxacin | 16 | $340 | $21 |
| Montelukast | 27 | $314 | $12 |
| Sulfamethoxazole-Trimethoprim | 49 | $238 | $5 |
| Pravastatin | 19 | $228 | $12 |
| Metoprolol | 36 | $220 | $6 |
| Alendronate | 23 | $162 | $7 |
| Fluticasone Propionate | 11 | $125 | $11 |
| Acyclovir | 13 | $84 | $6 |
| Amlodipine Besylate | 12 | $56 | $5 |
2017: 5 drugs
| Advair Diskus | 49 | $22,450 | $458 |
| Montelukast | 37 | $444 | $12 |
| Azithromycin | 35 | $360 | $10 |
| Prednisone | 23 | $232 | $10 |
| Pantoprazole | 21 | $208 | $10 |
2016: 3 drugs
| Advair Diskus | 14 | $6,003 | $429 |
| Azithromycin | 13 | $249 | $19 |
| Pantoprazole | 15 | $201 | $13 |
2015: 3 drugs
| Tacrolimus | 13 | $1,809 | $139 |
| Metoprolol | 13 | $192 | $15 |
| Sulfamethoxazole-Trimethoprim | 22 | $120 | $5 |
2014: 2 drugs
| Prednisone | 11 | $166 | $15 |
| Sulfamethoxazole-Trimethoprim | 15 | $75 | $5 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1841278652
- Licence
- CA A99306, VA 0101250564California A99306: Current · expires 2028-08-31
- Group
- Stanford Health Care
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RP1001X (207RP1001X); Internal medicine (207R00000X); Federal specialty code 207RC0200X (207RC0200X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-01-03
- NPI last updated
- 2024-04-17
- NPI record certified
- 2024-04-17
This is when the NPI record was last certified, not a medical board exam.